Hurwitz et al., 1985 - Google Patents
The covalent linking of two nucleotide analogs to antibodiesHurwitz et al., 1985
- Document ID
- 10108500991200418558
- Author
- Hurwitz E
- Kashi R
- Arnon R
- Wilchek M
- Sela M
- Publication year
- Publication venue
- Journal of medicinal chemistry
External Links
Snippet
Two anticancer drugs, antagonists of nucleic acids, were covalently linked to antibodies specifically reactive with B leukemia cells and thus with a potential possibility of drug targeting to the tumorsite. The drugs cytosine l-/3-D-arabinoside and 5-fluorouridine …
- 108090001123 antibodies 0 title abstract description 40
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raso et al. | Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells | |
| Hurwitz et al. | The covalent linking of two nucleotide analogs to antibodies | |
| Lichtenstein et al. | In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes | |
| FI102355B (en) | Process for the preparation of anthracycline immunoconjugates with the same binding link | |
| US5028697A (en) | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers | |
| US4401592A (en) | Pharmaceutical composition having antitumor activity | |
| Clark et al. | Exofacial photolabelling of the human erythrocyte glucose transporter with an azitrifluoroethylbenzoyl-substituted bismannose | |
| Forbes et al. | Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity. | |
| EP0259904A1 (en) | Advanced anticancer therapy and cytotoxic medicaments for its implementation | |
| SE462261B (en) | PHARMACEUTICAL COMPOSITION AND CONJUGATED OF MELFALAN AND NORMAL HUMANIMMUNOGLOBULIN WITH ANTITUMUM EFFECTS AND PROCEDURES FOR ITS PREPARATION | |
| US5840880A (en) | Receptor modulating agents | |
| WO1995027723A1 (en) | Receptor modulating agents and methods relating thereto | |
| JPH03502885A (en) | Method of treating tumor cells by inhibiting growth factor receptor function | |
| EA001200B1 (en) | PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT, METHOD OF INHIBITING IMMUNE RESPONSE | |
| Melmon et al. | Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones | |
| Chess et al. | Leukocyte inhibitory factor (LIF): Production by purified human T and B lymphocytes | |
| KR20030088056A (en) | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors | |
| JPS5843926A (en) | Selective carcinostatic agent | |
| Newman | Selective blockade of human natural killer cells by a monoclonal antibody. | |
| Edmiston et al. | In vivo induction of murine cytokine production by carcinoembryonic antigen | |
| Connors et al. | Studies on the mechanism of action of 5‐aziridinyl‐2, 4‐dinitrobenzamide (CB 1954), a selective inhibitor of the walker tumour | |
| Rosowsky | Methotrexate analogs. 2. Facile method of preparation of lipophilic derivatives of methotrexate and 3', 5'-dichloromethotrexate by direct esterification | |
| JPH08501535A (en) | Peptide drugs for treating diseases | |
| US5739287A (en) | Biotinylated cobalamins | |
| US5284834A (en) | Adenosine functionalized congeners as cardiovascular treating agents for animals and methods for using same |